Regadenoson – Key patent, SPC, and data exclusivity expiry (44 country coverage):Life Sciences Market Research Reports

Life Sciences Market Research Reports

Creating iOS Games: Beginner Course Marin Todorov teaches you how to create an iPhone game easily and simply using Cocos2d in this $99 online course. From our sponsors

Regadenoson – Key patent, SPC, and data exclusivity expiry (44 country coverage) Sep 14th 2013, 00:00, by rnrmahesh Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. This Pipeline Selector report covers Regadenoson Regadenoson indications: Diagnostic aid as a pharmacological stress agent for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress Regadenoson innovator: Astellas (Lexiscan); Gilead (Rapiscan) Examples of information found in this online report include: # Includes key patent publications for 44 countries (see list below) # Contains SPC protection … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=114775. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/regadenoson-key-patent-spc-and-data-exclusivity-expiry-44-country-coverage-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions